ACLX Arcellx, Inc.
USHealthcareAs of 2026-05-15 16:00
Why ACLX matters now
Arcellx, Inc. (ACLX) is a US stock in Healthcare. The latest InvestLog snapshot shows $115.07 with +0.02% on the session and $6.73B in market capitalization; recent performance reads 1-month +0.00% and YTD +76.49%.
The latest financial table shown here is Q4 2025, with revenue of $1.7M, net income of $-58.1M, and EPS of $-1.00. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -3.2%.
The latest indexable market news headline is "Gilead Sciences Completes Acquisition of Arcellx Ahead of Potential Commercial Launch of Anito-cel" from Business Wire.
Additional event context on this page matters because analyst consensus is Hold with a median target of $115.00; recent insider activity includes Elghandour Rami filing D-Return. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
16.10
P/S
302.09
EV/EBITDA
-34.09
DCF Value
$0.84
FCF Yield
-3.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
-64.8%
Operating Margin
-1135.6%
Net Margin
-1027.3%
ROE
-55.4%
ROA
-37.9%
ROIC
-49.9%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $1.7M | $-58.1M | $-1.00 |
| FY 2025 | $22.3M | $-228.9M | $-4.07 |
| Q3 2025 | $4.9M | $-55.8M | $-0.99 |
| Q2 2025 | $7.6M | $-52.8M | $-0.94 |
Analyst Ratings
Consensus
Hold
Target (Consensus)
$112.45
Target (Median)
$115.00
Target Range
$82.00 - $120.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.25
Arcellx, Inc. is a clinical-stage biotechnology enterprise dedicated to pioneering immunotherapeutic solutions for patients battling cancer and other intractable diseases. A cornerstone of their pipeline is CART-ddBCMA, an advanced ddCAR product candidate currently undergoing a Phase 1 clinical trial. This investigational treatment targets individuals suffering from relapsed or refractory multiple myeloma (MM). Beyond their lead candidate, Arcellx is also advancing ACLX-001, an immunotherapy composed of ARC-T cells and bi-valent SparX proteins engineered to combat r/r MM by targeting BCMA. Their development efforts extend to ACLX-002 and ACLX-003, designed to address relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), alongside a broader portfolio of additional AML/MDS candidates and programs focused on solid tumors. The company, headquartered in Gaithersburg, Maryland, was established in 2014. It operated as Encarta Therapeutics, Inc. before adopting its current name, Arcellx, Inc., in January 2016.